Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.67 |
| ▸ | TLR8 | Q9NR97 | 16/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861260 | 0.95 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL3863543 | 0.91 | TLR7 (0.63) | TLR7TLR8NUDT1 | |
| SCHEMBL483010 | 0.91 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL30345968 | 0.91 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL1753999 | 0.90 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL1490825 | 0.90 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL3862186 | 0.89 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL3865767 | 0.89 | TLR7 (0.80) | TLR7TLR8NUDT1 | |
| SCHEMBL3871138 | 0.87 | TLR7 (0.65) | TLR7TLR8NUDT1 | |
| SCHEMBL3863927 | 0.87 | TLR7 (0.54) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | claimed |
| EP-1651190-A4 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-15 | — | — | EP | claimed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | claimed |
| EP-1651190-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016275-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8221771-B2 | Formulations containing an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1651190-A4 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1651190-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005016275-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | IFNG, IRF3, ICOS | TLR7 18/4885TLR8 28/4885NUDT1 1398/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | TLR7 68/4885TLR8 220/4885NUDT1 648/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 68/4885TLR8 220/4885NUDT1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.